>>REDWOOD CITY, Calif., March 25 /PRNewswire/ -- With at least 25 companies either selling protein biochips today or preparing to enter the market within the next two years, sales in this industry are poised for enormous growth, according to a new report by BioInsights of Redwood City, California. In ``Protein Biochips: On the Threshold of Success,'' BioInsights presents a thorough analysis of both the technology and business strategies of 25 leading protein biochip makers. BioInsights predicts that sales of protein biochips will top $700 million in 2006, a ten-fold increase from sales of $76 million in 2001.
In the new report, a successor to BioInsights' popular ``Protein Chips: The Race for High-Throughput Protein Analysis (2000),'' the strategic consulting firm evaluates the strengths and weaknesses of each of the protein biochip makers, and assesses both opportunities and threats facing their products. BioInsights identifies the companies most likely to dominate specific market segments, as well as the companies most likely to play key supporting roles in moving the technology forward.
Based on interviews with company officials and leading academic researchers, BioInsights analyzes the protein biochip market from four different perspectives. ``Protein Biochips'' compares the market drivers for interaction biochips, used to study protein function and interactions, with the market drivers for capture biochips, used to profile protein expression. ``Protein Biochips'' also compares the market drivers for pre-fabricated protein biochips with the market drivers for tools used to assemble biochips.
In addition, the report examines the demand for protein biochips in drug discovery, drug validation, therapeutic development, pre-clinical and clinical trials, and diagnostics. Protein biochip technology will likely provide valuable specificity and selectivity data for screening small molecule and antibody therapeutics. It can also be used to identify the molecular signatures of disease states and drug responses.
BioInsights is a strategic consulting firm that specializes in emerging markets and technologies in biotechnology and pharmaceuticals. A leading authority on protein biochips, the firm was recently quoted in ``Science'' and ``Nature Biotechnology,'' and has presented work at two protein microarray conferences. BioInsights has an editorial board of leading protein biochip researchers -- Joanna Albala of the Lawrence Livermore National Laboratory, Brian Haab of the Van Andel Research Institute, and Thomas Joos of the Natural and Medical Sciences Institute at the University of Tuebingen -- who reviewed the ``Protein Biochips'' report.
``Protein Biochips: On the Threshold of Success'' is the sixth in a series of reports from BioInsights. For more information and to request a table of contents, contact BioInsights at 650-701-0280 or at marketing@bioinsights.net.<<
Cheers, Tuck |
